Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 19 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Revolution Medicines Inc | RVMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 37.45 | 09:18:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 37.45 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 5 | 19 | - | 15.4401 - 40.21 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:49:04 | 1 | $ 37.45 | USD |
Revolution Medicines Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 37.88M | 164.69M | - | 11.58M | -436.37M | -2.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Revolution Medicines News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 40.00 | 40.21 | 36.92 | 38.69 | 1,050,755 | -2.55 | -6.37% |
| 1 Month | 37.79 | 40.21 | 34.23 | 36.99 | 1,183,198 | -0.34 | -0.90% |
| 3 Months | 29.41 | 40.21 | 28.43 | 33.30 | 1,485,683 | 8.04 | 27.34% |
| 6 Months | 20.11 | 40.21 | 18.79 | 29.60 | 1,437,002 | 17.34 | 86.23% |
| 1 Year | 25.56 | 40.21 | 15.4401 | 27.80 | 1,573,917 | 11.89 | 46.52% |
| 3 Years | 29.42 | 40.21 | 14.08 | 25.86 | 1,058,026 | 8.03 | 27.29% |
| 5 Years | 29.35 | 56.18 | 14.08 | 27.42 | 877,653 | 8.10 | 27.60% |
Revolution Medicines Description
| Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
